NIMH funding on PrEP use Among Adolescent Girls and Young Women in sub-Sahara...HopkinsCFAR
Dr. Susannah Allison. Dr. Allison is a Program Officer at the National Institute of Mental Health within the Division of AIDS Research. She oversees a portfolio of research focused on the prevention of HIV infection among infants, children, and adolescents as well as research to enhance health outcomes among youth living with HIV. She is also the training director for the division. Prior to working at NIMH, Dr. Allison worked with children and families infected and affected by HIV in Baltimore, Miami, and Washington, DC. She completed her doctorate at George Washington University where she received her Ph.D. in Clinical Child Psychology with an emphasis in child health psychology.
HPV vaccine policies: How innovative partnerships led to policy relevant HPV vaccine research
Présentation de Gina Ogilvie au colloque "Recherche interventionnelle contre le cancer : Réunir chercheurs, décideurs et acteurs de terrain » - 17 et 18 novembre 2014, BnF, Paris
Madridge Journal of AIDS (ISSN: 2638-1958); Haiti is one of the most severely resource-constrained countries in the Americas, experiencing high rates of HIV. Access to HIV care is the paramount barrier with a paucity of specialized care providers throughout the very rural country.
Planning, Launching, and Sustaining Accreditation-worthy Postgraduate NP Resi...CHC Connecticut
Planning, Launching, and Sustaining Accreditation-worthy Postgraduate NP Residency Training Programs
Presented by CHC. Inc. and the Weitzman Institute
January 9, 2019 3:00pm (EST)
NIMH funding on PrEP use Among Adolescent Girls and Young Women in sub-Sahara...HopkinsCFAR
Dr. Susannah Allison. Dr. Allison is a Program Officer at the National Institute of Mental Health within the Division of AIDS Research. She oversees a portfolio of research focused on the prevention of HIV infection among infants, children, and adolescents as well as research to enhance health outcomes among youth living with HIV. She is also the training director for the division. Prior to working at NIMH, Dr. Allison worked with children and families infected and affected by HIV in Baltimore, Miami, and Washington, DC. She completed her doctorate at George Washington University where she received her Ph.D. in Clinical Child Psychology with an emphasis in child health psychology.
HPV vaccine policies: How innovative partnerships led to policy relevant HPV vaccine research
Présentation de Gina Ogilvie au colloque "Recherche interventionnelle contre le cancer : Réunir chercheurs, décideurs et acteurs de terrain » - 17 et 18 novembre 2014, BnF, Paris
Madridge Journal of AIDS (ISSN: 2638-1958); Haiti is one of the most severely resource-constrained countries in the Americas, experiencing high rates of HIV. Access to HIV care is the paramount barrier with a paucity of specialized care providers throughout the very rural country.
Planning, Launching, and Sustaining Accreditation-worthy Postgraduate NP Resi...CHC Connecticut
Planning, Launching, and Sustaining Accreditation-worthy Postgraduate NP Residency Training Programs
Presented by CHC. Inc. and the Weitzman Institute
January 9, 2019 3:00pm (EST)
We observed that 59% centers had staining facilities at the center. In 99% centers they had medicine
available all the time. 76% patients stated that the distance between centers and their residences is <1 kilometer. 97%
centers had accessible road to the centers. 76% providers knew consequences of treatment failure. 31% patients knew
the mode of transmission. 1% patients knew the duration of treatment. 73% patients knew consequences of treatment
failure.
Project RSP! Training on PrEP for HIV PreventionJim Pickett
This is a training on PrEP (pre-exposure prohylaxis) for HIV prevention, designed for people who work in the HIV prevention field. The training is designed by AIDS Foundation of Chicago's Project Ready, Set, PrEP! (RSP!). For more information on PrEP, visit the project's blog at www.myprepexperience.blogspot.com.
These slides were presented by Dr. Henry Nagai during JSI’s Index Testing & Partner Notification for HIV Epidemic Control webinar on April 11th, 2019. Dr. Nagai is currently the Project Director/Chief of Party for the JSI-implemented USAID Strengthening the Care Continuum project in Ghana with a focus on HIV and key populations. Using funding from USAID and PEPFAR, the Project is improving the capacity of the Government of Ghana and civil society partners to provide quality and comprehensive HIV services for key populations and people living with HIV.
Keeping It Real:Resources for Implementing Evidence-based Public Health Progr...MargaretFarrell
Through this workshop, participants will
not only become familiar with how to use the tools they need to identity and address health outcomes, but
understand the benefits of virtual communities of practice as a means to engage researchers and practitioners around implementing cancer control programs.
will introduce participants to the Cancer Control P.L.A.N.E.T portal and the Research to Reality Community of Practice. (#NCIR2R)
Presentation given at the NATIONAL HEALTH OUTREACH CONFERENCE (#NHOC) Promoting Connections to Create Healthy Individuals, Families and Communities May 8, 2015
HIV Index Testing: The USAID DISCOVER-Health Project Experience in Zambia JSI
This was presented by Kalasa Mwansa during the Index Testing & Partner Notification for HIV Epidemic Control webinar on April 11th, 2019. The USAID DISCOVER- Health Project Experience aims to increase the use of high quality, integrated health services in specific target groups, and to provide integrated health products and services in a sustainable manner. In addition, it aims to contribute to HIV epidemic control and provides HIV index testing at every ART site.
We observed that 59% centers had staining facilities at the center. In 99% centers they had medicine
available all the time. 76% patients stated that the distance between centers and their residences is <1 kilometer. 97%
centers had accessible road to the centers. 76% providers knew consequences of treatment failure. 31% patients knew
the mode of transmission. 1% patients knew the duration of treatment. 73% patients knew consequences of treatment
failure.
Project RSP! Training on PrEP for HIV PreventionJim Pickett
This is a training on PrEP (pre-exposure prohylaxis) for HIV prevention, designed for people who work in the HIV prevention field. The training is designed by AIDS Foundation of Chicago's Project Ready, Set, PrEP! (RSP!). For more information on PrEP, visit the project's blog at www.myprepexperience.blogspot.com.
These slides were presented by Dr. Henry Nagai during JSI’s Index Testing & Partner Notification for HIV Epidemic Control webinar on April 11th, 2019. Dr. Nagai is currently the Project Director/Chief of Party for the JSI-implemented USAID Strengthening the Care Continuum project in Ghana with a focus on HIV and key populations. Using funding from USAID and PEPFAR, the Project is improving the capacity of the Government of Ghana and civil society partners to provide quality and comprehensive HIV services for key populations and people living with HIV.
Keeping It Real:Resources for Implementing Evidence-based Public Health Progr...MargaretFarrell
Through this workshop, participants will
not only become familiar with how to use the tools they need to identity and address health outcomes, but
understand the benefits of virtual communities of practice as a means to engage researchers and practitioners around implementing cancer control programs.
will introduce participants to the Cancer Control P.L.A.N.E.T portal and the Research to Reality Community of Practice. (#NCIR2R)
Presentation given at the NATIONAL HEALTH OUTREACH CONFERENCE (#NHOC) Promoting Connections to Create Healthy Individuals, Families and Communities May 8, 2015
HIV Index Testing: The USAID DISCOVER-Health Project Experience in Zambia JSI
This was presented by Kalasa Mwansa during the Index Testing & Partner Notification for HIV Epidemic Control webinar on April 11th, 2019. The USAID DISCOVER- Health Project Experience aims to increase the use of high quality, integrated health services in specific target groups, and to provide integrated health products and services in a sustainable manner. In addition, it aims to contribute to HIV epidemic control and provides HIV index testing at every ART site.
Co-ordinated malaria research for better policy and practice: the role of res...ACT Consortium
Prof. David Schellenberg from the London School of Hygiene & Tropical Medicine presents on behalf of the ACT Consortium at the European Congress on Tropical Medicine and International Health in Basel, Switzerland, 8 September 2015
Overview of the 2018 Update to the Integrated Plan and PrEP Workgroup Draft R...Office of HIV Planning
Mari Ross-Russell (Office of HIV Planning) and Matthew McClain (Public Health Policy & Planning Consultant) presented these slides to the PrEP Workgroup of the Philadelphia EMA HIV Integrated Planning Council on January 16, 2019.
Developing a national strategy to bring pathogen genomics into practiceExternalEvents
http://www.fao.org/about/meetings/wgs-on-food-safety-management/en/
Developing a national strategy to bring pathogen genomics into practice. Presentation from the Technical Meeting on the impact of Whole Genome Sequencing (WGS) on food safety management and GMI-9, 23-25 May 2016, Rome, Italy.
Maternal and newborn health: some experiences and roles of the WCH Knowledge Hub in Asia and the Pacific
Chris Morgan
Principal Fellow, Centre for International Health
Burnet Institute
Rare Diseases SA has been actively improving the quality of life for those impacted by Rare Diseases over the last 5 years.
Our key focus areas have remained advocacy, patient navigation and community engagement, and through these strategic objectives we have successfully managed to see positive impact in our community.
From the development of over 80 patient connect points, to the implementation of a mobile app, RDSA has ensured patients remain supported and connected whilst the organization remains focused on our advocacy efforts.
The successful roll-out of our Rare Assist service has also seen a reduction in out of pocket costs for patients in the private sector.
We have attached our 5 year impact report which demonstrates some of the impact our work has had within our community. We have also included our programme overview of the Rare Assist Programme.
We would love to have your feedback on these reports, as well as feedback on the following questions:
1. What interest do you have with our organisation?
2. What is your current opinion on our work?
3. How would you like to stay informed about what we do?
4. What motivates you to stay connected with us?
Should you have any questions for us, we would love to hear from you.
Kind Regards
Kelly du Plessis
CEO -Rare Diseases South Africa
info@rarediseases.co.za
PrEP Implementation Planning for the USCHAMP Network
CHAMP Monthly Teleconference Training - PrEP's the Word: Everyone's Talking About It... But What Do We Need To Know, And Do, About Pre-Exposure Prophylaxis
Similar to Prevention Sciences Program: Present and Future (20)
NIH AIDS Executive Committee (NAEC) FY 2019 Ending the HIV Epidemic (EHE) in ...HopkinsCFAR
The NIH Office of AIDS Research (OAR) is pleased to release the NIH AIDS Executive Committee (NAEC) FY 2019 Ending the HIV Epidemic (EHE) in the U.S. Report.
High Sensitivity HIV Testing and Translational Science around PrEPHopkinsCFAR
Joanne Stekler, MD MPH
Associate Professor, Department of Medicine
University of Washington
Inter-Center for AIDS ResearchAntiretroviralsfor Prevention Working Group
November 13, 2017
Providing safe, affirming and evidence based care for transgender persons: Th...HopkinsCFAR
Tonia Poteat, PhD, PA-C, MPH
Assistant Professor
Johns Hopkins Bloomberg School of Public Health
Jean-Michel Brevelle
Sexual Minorities Program Manager
Maryland Department of Health and Mental Hygiene
Johns Hopkins School of Medicine
August 5, 2016
How to Split Bills in the Odoo 17 POS ModuleCeline George
Bills have a main role in point of sale procedure. It will help to track sales, handling payments and giving receipts to customers. Bill splitting also has an important role in POS. For example, If some friends come together for dinner and if they want to divide the bill then it is possible by POS bill splitting. This slide will show how to split bills in odoo 17 POS.
We all have good and bad thoughts from time to time and situation to situation. We are bombarded daily with spiraling thoughts(both negative and positive) creating all-consuming feel , making us difficult to manage with associated suffering. Good thoughts are like our Mob Signal (Positive thought) amidst noise(negative thought) in the atmosphere. Negative thoughts like noise outweigh positive thoughts. These thoughts often create unwanted confusion, trouble, stress and frustration in our mind as well as chaos in our physical world. Negative thoughts are also known as “distorted thinking”.
Ethnobotany and Ethnopharmacology:
Ethnobotany in herbal drug evaluation,
Impact of Ethnobotany in traditional medicine,
New development in herbals,
Bio-prospecting tools for drug discovery,
Role of Ethnopharmacology in drug evaluation,
Reverse Pharmacology.
Instructions for Submissions thorugh G- Classroom.pptxJheel Barad
This presentation provides a briefing on how to upload submissions and documents in Google Classroom. It was prepared as part of an orientation for new Sainik School in-service teacher trainees. As a training officer, my goal is to ensure that you are comfortable and proficient with this essential tool for managing assignments and fostering student engagement.
Unit 8 - Information and Communication Technology (Paper I).pdfThiyagu K
This slides describes the basic concepts of ICT, basics of Email, Emerging Technology and Digital Initiatives in Education. This presentations aligns with the UGC Paper I syllabus.
The Roman Empire A Historical Colossus.pdfkaushalkr1407
The Roman Empire, a vast and enduring power, stands as one of history's most remarkable civilizations, leaving an indelible imprint on the world. It emerged from the Roman Republic, transitioning into an imperial powerhouse under the leadership of Augustus Caesar in 27 BCE. This transformation marked the beginning of an era defined by unprecedented territorial expansion, architectural marvels, and profound cultural influence.
The empire's roots lie in the city of Rome, founded, according to legend, by Romulus in 753 BCE. Over centuries, Rome evolved from a small settlement to a formidable republic, characterized by a complex political system with elected officials and checks on power. However, internal strife, class conflicts, and military ambitions paved the way for the end of the Republic. Julius Caesar’s dictatorship and subsequent assassination in 44 BCE created a power vacuum, leading to a civil war. Octavian, later Augustus, emerged victorious, heralding the Roman Empire’s birth.
Under Augustus, the empire experienced the Pax Romana, a 200-year period of relative peace and stability. Augustus reformed the military, established efficient administrative systems, and initiated grand construction projects. The empire's borders expanded, encompassing territories from Britain to Egypt and from Spain to the Euphrates. Roman legions, renowned for their discipline and engineering prowess, secured and maintained these vast territories, building roads, fortifications, and cities that facilitated control and integration.
The Roman Empire’s society was hierarchical, with a rigid class system. At the top were the patricians, wealthy elites who held significant political power. Below them were the plebeians, free citizens with limited political influence, and the vast numbers of slaves who formed the backbone of the economy. The family unit was central, governed by the paterfamilias, the male head who held absolute authority.
Culturally, the Romans were eclectic, absorbing and adapting elements from the civilizations they encountered, particularly the Greeks. Roman art, literature, and philosophy reflected this synthesis, creating a rich cultural tapestry. Latin, the Roman language, became the lingua franca of the Western world, influencing numerous modern languages.
Roman architecture and engineering achievements were monumental. They perfected the arch, vault, and dome, constructing enduring structures like the Colosseum, Pantheon, and aqueducts. These engineering marvels not only showcased Roman ingenuity but also served practical purposes, from public entertainment to water supply.
How to Create Map Views in the Odoo 17 ERPCeline George
The map views are useful for providing a geographical representation of data. They allow users to visualize and analyze the data in a more intuitive manner.
2. Overview
• Orientation to PSP
• Program Objectives
• Major Projects/Programs
– Contracts
– Programs
– Networks
• Future Scientific Directions
DAIDS/PSP
3. Office of the Director
Sheryl Zwerski, Acting Director
Fulvia Veronese, Assistant Director
Cherlynn Mathias, Program Grants Coordinator
A J Reece, Program Assistant
Millicent Moye, Program Assistant
John Wroblewski, Program Specialist
Preclinical Microbicide
and Prevention
Research Branch
Jim Turpin, Chief
James Cummins
Leslie Marshall
Anabel Lowry
Kristen Porter
Hans Spiegel
Mike Gilbreath
Clinical Microbicide
Research Branch
Roberta Black, Chief
Jeanna Piper, Deputy
Lydia Soto-Torres
Grace Chow
Lester Freeman
Naana Cleland
Prevention Sciences Program
Clinical Prevention
Research Branch
David Burns, Chief
Vanessa Elharrar, Deputy
Wairimu Chege
Alain Kouda
Elizabeth Flanagan
Usha Sharma
Annie Waterman
Maternal, Adolescent, &
Pediatric Research
Branch
Devasena Gnanashanmugam
Chief
Betsy Smith
Patrick Jean-Philipe
Judi Miller
Ellen O’Gara
Renee Browning
November 10, 2014 *Contractor
4. PSP Objectives
1.) Deliver prevention tools that can reduce HIV
incidence in populations at risk by:
– Creating and sustaining a pipeline for non-vaccine
HIV prevention products using rational development
algorithms with clear go/no go criteria focused on:
• Sustained delivery methods
• Combination products (combination ARVs and
MPTs)
DAIDS/PSP
5. PSP Objectives
• Supporting clinical product development activities
that include appropriate safety and efficacy testing as
well as integrated PK/PD assessments and advance
HIV prevention candidates to licensure, specifically:
–Topical microbicides (vaginal and rectal)
–Systemic pre-exposure prophylaxis (PrEP)
–Other novel prevention products (including
biological, drugs and devices)
DAIDS/PSP
6. PSP Objectives
• Supporting efforts to improve treatment as
prevention by optimizing the testing, linkage to care
and treatment cascade.
2.) Support efforts to optimize HIV treatment for
pregnant women, infants, children, and adolescents.
DAIDS/PSP
7. PSP Objectives
3.) Contribute significantly to the advancement of
DAIDS cure agenda in infants and children.
4.) Supports efforts to transform the diagnosis,
prevention, and treatment of TB and other co-infections
of importance in the maternal/child
population.
DAIDS/PSP
8. PSP Objectives
5.) Partner with our NIMH and NIDA colleagues in both the clinical
and the preclinical arenas to incorporate behavioral research:
• ADHERENCE
• Accurate assessment of likelihood of intervention uptake
• Assessment of risk for ppts and providers
• Effective coping with stigma
• Substance use’s effects on all of the above
– Development of strategies to effectively engage this
population
DAIDS/PSP
9. Contract Resources for Microbicides and Prevention
3 Current Work Scopes
•Gap-Filling
•Development Planning
•Best Practice Working Groups (BPWG)
Accomplishments:
•Collaborating with Merck with IND enabling preclinical toxicity studies for
combination vaginal ring
•Supported MTN 013 with extractable and leachable studies
•Optimizing biophysical properties of single and combo ARV ring for IPM
•Performed multiple rabbit vaginal and rectal irritation studies to enable
Phase I studies
Future:
•RFP in development
DAIDS/PSP
10. Preclinical Programs
Mucosal Environment and HIV Prevention (MEHP)
Objective: Enhancement of HIV microbicide, PrEP and MPT
prevention strategy efficacy and safety by understanding their
interaction with the male and female genital and GI mucosa and
optimizing that interaction to better promote inhibition of HIV
transmission and acquisition
Accomplishments:
• Robust responses with varied topics of exploration
Future:
• Current round of funding should assure robust investigations
on the topic and consideration of future iterations is underway
DAIDS/PSP
11. Preclinical Programs
Preclinical Innovation Program (PIP)
Objective: Preclinical discovery and testing of single and
combination drug strategies and promotion of the
integration of new safety, efficacy and adherence
technologies into the prevention pipeline.
Accomplishments:
• Robust response which included truly innovative delivery
systems and validation of needed safety models
Future:
• Under consideration given fiscal constraints and
program needs
DAIDS/PSP
12. Preclinical Programs
Integrated Preclinical/Clinical Program (IPCP)
Objective: Stimulate a strong, diverse base in preclinical
discovery and development of new topical microbicides and
biomedical prevention for vaginal, rectal, penile and
oral/injectable use and support translation from preclinical to pre-
Phase 1 clinical studies
Accomplishments
• CROI 2014 presentation of first in human film study
• First testing of rectal specific TFV gel
• Begun pre-phase I study of TDF IVR with novel ring
platform
Future
• Future program needs being considered
DAIDS/PSP
13. Preclinical Programs
Sustained Release of Antivirals for Treatment and Prevention
(Collaboration between PSP and TRP)
Objective: Build a pipeline of long acting release formulations for non-vaccine
biomedical prevention (microbicide, PrEP) and therapeutic
candidates with a goal of a minimum of once a month dosing
Accomplishments:
• PAR and FOA released earlier in 2014
Future:
• Consideration underway for best way to stimulate the area for
prevention
DAIDS/PSP
14. Clinical Programs
Methods for Prevention Packages Program (MP3)
Objective: Increase collaborations between behavioral and
biomedical clinical scientists, modelers, and clinical trialists to
facilitate the design and testing of combination HIV prevention
interventions (prevention packages)
Accomplishments:
• First 6 projects are completing
• Packages must be population and region/locality specific
• Cost effectiveness of package is epidemic context
dependent
Future:
• Received robust response to recent PAs
DAIDS/PSP
15. Clinical Programs
Increased Knowledge and Innovative Strategies to Reduce HIV Incidence
(iKnow)
Objective: Promote innovative research to improve our ability to identify
populations that are both at high risk of HIV-1 infection and have a high
proportion of persons that are unaware of their HIV status, and to
successfully link them to HIV testing, effective prevention interventions, and,
if HIV-positive, care and treatment
Accomplishments:
• PAR released and robust response received
Future:
• Need is well documented, future funding uncertain
DAIDS/PSP
17. IMPAACT Mission
• Areas of focus for pregnant women and
children
– HIV Treatment
– HIV Prevention
– HIV Cure
– HIV Co-morbidities & Complications
– TB diagnosis, treatment, and prevention
19. HPTN Mission
• Discover and develop new and innovative
research strategies to reduce the acquisition
and transmission of HIV.
– Develops systemic PrEP, including long-acting
products
– Does not develop vaccines or microbicides, but
integrates once efficacy data available
21. MTN Mission
• Bring together investigators, community, and industry partners to
work on the development and rigorous evaluation of promising
microbicides – products applied inside the vagina or rectum that
are intended to prevent the sexual transmission of HIV.
• Collect the kind of data regulatory agencies require for determining
whether to approve a product for widespread use.
• Behavioral and social science is embedded within each study to gain
understanding of the needs and desires of different high-risk
groups.
• Include populations considered among those at highest risk,
including women in Sub-Saharan Africa, adolescents, pregnant and
breastfeeding women, transgender women and men who have sex
with men (MSM).
22. The Future for Prevention
Sciences Program
• Build a pipeline of sustained release products for prevention
– Topical micobicides
– PrEP
• Increase contextual awareness
– Micro & Macro environments
• Mucosal level
• Population level
DAIDS/PSP
23. The Future for Prevention
Sciences Program
• Integrate behavior into all phases of study, including
preclinical
– Understand what women (and men) want
• Lessons learned must remain at the forefront of all
future work
• Explore innovative trial methodologies/evidence required for
moving prevention products and packages forward
DAIDS/PSP
24. The Future for Prevention
Sciences Program
• Sharpen focus on the Testing & Treatment Cascade
– Improve testing strategies for most at risk
– Improve linkage and engagement in care
• Support testing of integrated prevention strategy packages
that are appropriate, acceptable and cost effective for target
populations
• Increase efforts to deliver strategies that can be scaled up to
reduce incidence in adolescents
– Young MSM globally
– Females in SSA
DAIDS/PSP
25. The Future for Prevention Sciences
• Focus on achieving appropriate safety and PK/PD of new ARVs
for pregnant women, children and adolescents
– Optimize first line treatment from infancy through adolescence
• Partner with other DAIDS programs, ICs, and agencies to
explore all reasonable efforts to explore infant cure
• Partner with other DAIDS programs, NIAID divisions, ICs and
outside donors to improve TB diagnosis, prevention, and
treatment for pregnant women and children
DAIDS/PSP
Program
26. Prevention Sciences Program Pipeline
Discovery Preclinical
IIMMPPAAAACCTT NNeettwwoorrkk
Prevention Trials
Network
Microbicide Trials
Network
Preclinical I Pre-
II III
Studies
Phase I
(Critical Path)
Studies
Virology Clinical Studies
MP3-III (PA)
Comprehensive Resources for Topical Microbicides
and Biomedical Prevention (CRMP)
Mucosal Environment
and HIV Prevention
(MEHP II)
Prevention Innovation
Program (PIP)
Sustained Release Program for non-Vaccine
Biomedical Prevention and Therapeutics
(SRP-nBPT)
Integrated Preclinical Clinical Program
for Microbicides and Biomedical
Prevention (IPCP-MBP)
IKNOW (PA)
